HNN3.0

Project cooperationUpdated on 23 January 2026

Seeking collaboration in ATMP and New Approach Methodologies

Immunotherapy Group Leader at Łukasiewicz Research Network - PORT Polish Center for Technology Development

Wrocław, Poland

About

I am a member of the team implementing a Horizon Europe – Teaming for Excellence project aimed at establishing a Centre of Excellence in BioDataBanking and Precise Phenotyping in Wroclaw (Poland). Within this initiative, I am responsible for the Cell-engineering and Cell-based Therapies technology platform, which supports the full translational pathway of Advanced Therapy Medicinal Products (ATMPs) and the development of advanced experimental models relevant to New Approach Methodologies (NAMs).

The platform’s scope includes:

  • development and optimisation of advanced cell engineering approaches for cell-based therapies,

  • standardisation of ATMP manufacturing processes (early GMP-readiness, Quality-by-Design principles),

  • development of advanced preclinical and functional models, including human-relevant cellular systems applicable to NAMs,

  • translational integration linking laboratory innovation with clinical application and regulatory requirements.

Current activities focus on γδ T-cell-based immunotherapy for glioblastoma multiforme, optimised toward a therapeutic ATMP cell product. We collaborate closely with regional clinical centres interested in early-phase clinical trials. In parallel, a project proposal is under evaluation for a similar γδ T-cell-based approach in ovarian cancer.

These translational efforts are conducted in partnership with:

  • Lower Silesian Oncology, Hematology and Pulmonology Center, the largest regional comprehensive cancer centre, and

  • Regional Blood Transfusion and Blood Treatment Center in Poznań, which operates a licensed cell therapy manufacturing facility.

What I offer to consortia

  • hands-on expertise in ATMP development, standardisation, and early GMP-readiness,

  • development of human-relevant cellular and preclinical models supporting NAMs implementation in biomedical research and regulatory contexts,

  • experience in building and operating Centre of Excellence infrastructures,

  • strong links to clinical centres, public healthcare systems, and manufacturing facilities in a widening-country context.

What I am looking for

Partners and coordinators for Horizon Europe consortia addressing:

  • HORIZON-HLTH-2026-01-TOOL-03: integration and validation of NAMs for biomedical research and regulatory testing,

  • HORIZON-HLTH-2026-01-TOOL-07: establishment of a European network of Centres of Excellence for ATMPs, including policy, roadmap development, education, and translation.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Partner seeks Consortium/Coordinator

Similar opportunities

  • Project cooperation

    Contributing manufacturing technologies and clinical trial experience to a European network of Centres of Excellence for ATMPs

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

    Michael Apel

    Scientific Director - Grants and Collaborations @ R&D Department at Miltenyi Biotec

    Bergisch Gladbach, Germany

  • Project cooperation

    Nanolive – Cooperation Profile

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Yann Cotte

    CEO at Nanolive

    Tolochenaz, Switzerland

  • Project cooperation

    Biotech looking for collaboration partners: Cell therapy and cell-derived products

    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices

    Moayed Hamza

    CEO & Founder at HAON Life Science

    Dublin, Ireland